While some of the mutations are oncogenic (i.e., IDH1/2, EZH2, and DNMT3A), others are tumor suppressive (i.e., KDM6A, CREBBP/EP300, and SMARCB1) [6]. The gene discussed is EP300; the disease is neoplasm.